These Stocks are Flying with the Eagles

February 10, 2025

DENVER, Colo., Feb 10, 2025 (247marketnews.com)- 24/7 Market News, a trusted source for real-time financial news and market analysis, highlights today’s most significant stock movements and breaking developments shaping the financial landscape.

Biodexa Pharmaceuticals (NASDAQ:BDRX) reported that the US Food and Drug Administration (“FDA”) granted Fast Track designation for eRapa. eRapa is Biodexa’s proprietary encapsulated form of rapamycin for the treatment of familial adenomatous polyposis (FAP). Fast track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

Momentus (NASDAQ:MNTS) stated that it was awarded a contract expansion by the U.S. Department of Defense. Momentus will conduct an in-orbit demonstration of the assembly of large-scale structures for the Defense Advanced Research Projects Agency (DARPA).

For this upcoming mission, which will launch on an upcoming SpaceX Transporter rideshare as soon as early 2026, Momentus will provide full-service support to the DARPA Novel Orbital and Moon Manufacturing, Materials, and Mass-efficient Design (NOM4D) program, including arranging launch services, payload integration, and in-orbit hosting of the payload for a complex in-space assembly mission.

The CEO of Momentus, John Rood, stated, “We’re thrilled to be supporting DARPA on this cutting-edge program and are looking forward to this exciting demonstration of key enabling technologies for in-space assembly. Cost-effective assembly of structures in space has the potential to transform how we operate in space. Structures that are too large to fit within the shroud of a launch vehicle can be robotically assembled in space, leading to less complex and cost-effective structures like large communications antennas, hubs for orbital manufacturing of advanced materials and potentially products like semi-conductors, and the repair and upgrade of space systems. This latest contract from DARPA builds on work Momentus has done to secure important contracts from NASA and the U.S. Space Development Agency in late 2024 to support missions in orbit to demonstrate new technology. Together, these contracts position the company well for future growth.”

Gorilla Technology (NASDAQ:GRRR) reported closing its At-The-Market (ATM) funding program, about which Jay Chandan, Gorilla’s Chairman and CEO, commented, “We made a commitment to our shareholders that we would not dilute and we are standing by that promise. By closing our ATM program, we are ensuring that shareholder value remains protected while reinforcing our position as a disciplined and strategic company. Our focus remains on strong execution, revenue expansion and delivering long-term value to our investors.”

NLS Pharmaceutics (NASDAQ:NLSP) and Kadimastem stated that their expected merger aims to transform the treatment landscape for complex conditions such as diabetes. NLS and Kadimastem believe that this merger is positioned to potentially create holistic solutions. Their CEOs said, “Together, we will advance innovative solutions to better address the challenges of diabetes and related disorders.”

Multiple AI listings, like Palladyne AI (NASDAQ:PDYN) and Brand Engagement Network (NASDAQ:BNAI), are trading higher today.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (BDRX, MNTS, GRRR, NLSP, PDYN, BNAI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.